Bone Tumor Medical Services in China

Bone tumors are abnormal growths of cells within bone tissue, classified as either primary—originating in bone (e.g., osteosarcoma, chondrosarcoma, Ewing sarcoma)—or secondary, resulting from metastasis of cancers such as breast, prostate, or lung carcinoma. Symptoms often include persistent localized pain, swelling, pathologic fracture, or unexplained weight loss. Diagnosis relies on multimodal imaging—including MRI, CT, and bone scintigraphy—followed by biopsy for histopathological confirmation and molecular profiling. Treatment is highly individualized, integrating surgical resection (limb-sparing procedures or endoprosthetic reconstruction), neoadjuvant and adjuvant chemotherapy, radiotherapy (including intensity-modulated and proton beam therapy), and emerging targeted or immunotherapeutic approaches. Prognosis depends on tumor type, grade, stage, resectability, and response to systemic therapy.

China offers distinct advantages for international patients seeking bone tumor care. Leading orthopedic oncology centers—such as Peking University People’s Hospital and Shanghai Jiao Tong University Affiliated Sixth People’s Hospital—boast internationally trained surgeons, multidisciplinary tumor boards, and access to advanced technologies including intraoperative navigation, 3D-printed custom implants, and next-generation sequencing for precision oncology. Five-year survival rates for localized osteosarcoma exceed 70% in high-volume centers, supported by robust clinical outcome data published in journals like *Journal of Bone and Joint Surgery* and *European Journal of Cancer*. Crucially, comprehensive treatment—including diagnostics, surgery, rehabilitation, and follow-up—is typically 40–60% more cost-effective than in the US or Western Europe, without compromising evidence-based standards.

As a dedicated medical tourism agency, we facilitate seamless cross-border care: verifying hospital accreditation, coordinating appointments with certified orthopedic oncologists, providing transparent itemized pricing in advance, arranging visa support, accommodation, and real-time interpretation—all while ensuring continuity of care and post-treatment follow-up guidance.

Treatment Options & Itemized Cost Breakdown: Bone Tumors (Orthopedics)

Non-Surgical / Conservative / Medication Options

*Indicated for benign lesions, low-grade malignancies under surveillance, palliation, or preoperative neoadjuvant therapy.*

• •NSAIDs & Analgesics (e.g., celecoxib, tramadol): ¥80–¥300/month ($11–$42)
• •Bisphosphonates (zoledronic acid IV, 4 mg/infusion): ¥1,200–¥1,800/dose ($167–$250) — requires renal function testing (¥120, $17)
• •Denosumab (120 mg SC, monthly): ¥4,500–¥5,200/dose ($625–$722) — includes mandatory calcium/vitamin D monitoring (¥280, $39)
• •Radiation Therapy (Palliative): 5–10 fractions; ¥12,000–¥25,000/course ($1,667–$3,472) — includes CT simulation (¥800, $111) and dosimetry planning (¥1,500, $208)

Surgical / Procedural / Interventional Options

*Eligibility: Confirmed diagnosis via biopsy, adequate cardiopulmonary reserve, no distant metastasis (except for palliative stabilization).*

• •Curettage + Bone Grafting (benign aggressive tumors): ¥28,000–¥42,000 ($3,890–$5,833)
• •Wide Resection + Endoprosthesis (malignant, e.g., osteosarcoma): ¥65,000–¥98,000 ($9,030–$13,610) — includes custom prosthesis (¥22,000–¥45,000, $3,055–$6,245)
• •Limb-Salvage Surgery with Modular Implant: ¥72,000–¥105,000 ($10,000–$14,580)
• •Preoperative Workup: MRI (¥1,600, $222), PET-CT (¥7,200, $1,000), core needle biopsy (¥1,400, $194), cardiac echo (¥600, $83)

Special / Complex Condition Options

• •Metastatic Bone Disease (Pathologic Fracture Risk): Radiofrequency ablation + cementoplasty — ¥18,000–¥26,000 ($2,500–$3,610)
• •Chondrosarcoma (Grade II/III) requiring En Bloc Resection: ¥85,000–¥120,000 ($11,800–$16,660)
• •Neoadjuvant Chemotherapy (Osteosarcoma/Ewing): 2–4 cycles (doxorubicin/cisplatin/ifosfamide); ¥15,000–¥28,000/cycle ($2,083–$3,890) — includes weekly CBC/LFTs (¥180/test, $25)

Quick Selection Guide

• •<18 years, high-grade sarcoma: Prioritize wide resection + endoprosthesis + neoadjuvant chemo (total estimated ¥180,000–¥250,000, $25,000–$34,700)
• •>65 years, comorbidities, solitary metastasis: Palliative radiotherapy + denosumab + cementoplasty (¥35,000–¥52,000, $4,860–$7,220)
• •Benign (e.g., giant cell tumor) without fracture: Curettage + bone grafting ± adjuvant phenol/cryo (¥32,000–¥45,000, $4,440–$6,245)
• •Budget-constrained (<¥30,000): Bisphosphonates + NSAIDs + serial MRI monitoring (¥2,500–¥4,000/year, $350–$560) — only for stable, non-aggressive lesions confirmed histologically.